SIGA Technologies, Inc. (SIGA) Bundle
Understanding SIGA Technologies, Inc. (SIGA) Revenue Streams
Understanding SIGA Technologies, Inc.’s Revenue Streams
The revenue analysis of SIGA Technologies, Inc. for the year 2024 reveals significant growth and diversification across its revenue streams. The breakdown of primary revenue sources is as follows:
- Product Sales and Supportive Services: For the nine months ended September 30, 2024, total revenues from product sales and supportive services amounted to $53.5 million, which includes:
- $17.6 million from IV TPOXX® sales to the U.S. Government under the 19C BARDA Contract.
- $22.8 million from oral TPOXX® sales to the U.S. Government under the same contract.
- $11.8 million from international sales of oral TPOXX®.
- Approximately $1.1 million from oral TPOXX® sales to the DoD.
- In comparison, for the nine months ended September 30, 2023, revenues from product sales and supportive services were $14.9 million, primarily derived from:
- Approximately $5.1 million of oral TPOXX® sales to the DoD.
- Approximately $9.1 million from international sales of oral TPOXX®.
The year-over-year revenue growth rate shows a substantial increase of approximately 259% from 2023 to 2024 in the product sales and supportive services segment.
Revenue from Research and Development Activities
Revenues from research and development activities for the nine months ended September 30, 2024, totaled $3.8 million, a decrease from $8.5 million in the same period of 2023. This decline is primarily due to the completion of billable activities under the PEP Label Expansion R&D Contract, which previously contributed significant revenue.
Contribution of Different Business Segments to Overall Revenue
The contribution of different business segments to overall revenue can be summarized in the following table:
| Segment | Revenue (2024) | Revenue (2023) | Year-over-Year Growth |
|---|---|---|---|
| Product Sales and Supportive Services | $53.5 million | $14.9 million | 259% |
| Research and Development | $3.8 million | $8.5 million | -55% |
| Total Revenue | $57.3 million | $23.4 million | 144% |
Significant Changes in Revenue Streams
The most notable change in revenue streams is the substantial increase in product sales and supportive services, driven by increased sales to the U.S. Government and international markets. The revenue from research and development has significantly decreased, reflecting the completion of key contracts that previously generated substantial income. For the three months ended September 30, 2024, revenues from product sales and supportive services were $8.9 million, compared to $8.0 million in the same period of 2023, indicating a growth trend in this segment as well.
Overall, the growth in product sales coupled with a decline in research and development revenue highlights a shifting focus towards market-driven sales while transitioning away from reliance on government contracts for research funding.
A Deep Dive into SIGA Technologies, Inc. (SIGA) Profitability
A Deep Dive into SIGA Technologies, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was approximately 68.3%, calculated from revenues of $53.5 million and cost of sales of $17.2 million. In comparison, for the nine months ended September 30, 2023, the gross profit margin was approximately 79.9% with revenues of $14.9 million and cost of sales of $3.0 million.
Operating Profit Margin: The operating profit for the nine months ended September 30, 2024, was $18.1 million, leading to an operating margin of approximately 33.8%. For the same period in 2023, the operating loss was ($1.2 million), resulting in a negative operating margin.
Net Profit Margin: The net profit for the nine months ended September 30, 2024, was $13.5 million, translating to a net profit margin of approximately 23.6%. In contrast, the net loss for the nine months ended September 30, 2023, was ($4.2 million), yielding a net profit margin of (17.9%).
| Metric | 2024 | 2023 |
|---|---|---|
| Gross Profit Margin | 68.3% | 79.9% |
| Operating Profit Margin | 33.8% | (8.0%) |
| Net Profit Margin | 23.6% | (17.9%) |
Trends in Profitability Over Time: The shift from a net loss of ($4.2 million) in 2023 to a net profit of $13.5 million in 2024 indicates a significant recovery in profitability. The gross profit margin decreased from 79.9% to 68.3%, reflecting increased costs associated with higher sales volumes.
Comparison of Profitability Ratios with Industry Averages: The average net profit margin for the biotechnology industry is around 20%. Thus, the company’s current net profit margin of 23.6% positions it slightly above the industry average, suggesting competitive profitability metrics.
Analysis of Operational Efficiency: Selling, general and administrative (SG&A) expenses for the nine months ended September 30, 2024, were $18.2 million, compared to $14.7 million in 2023, reflecting an increase of approximately $3.5 million due to higher international promotion fees and increased compensation expenses. Research and development (R&D) expenses decreased to $9.0 million in 2024 from $13.8 million in 2023, indicating improved cost management in R&D activities.
| Expense Type | 2024 | 2023 |
|---|---|---|
| SG&A Expenses | $18.2 million | $14.7 million |
| R&D Expenses | $9.0 million | $13.8 million |
Gross Margin Trends: The gross margin trend indicates a decrease from 79.9% in 2023 to 68.3% in 2024, primarily due to increased cost of sales associated with growing production to meet government contracts.
Debt vs. Equity: How SIGA Technologies, Inc. (SIGA) Finances Its Growth
Debt vs. Equity: How SIGA Technologies, Inc. Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, SIGA Technologies reported total liabilities of $25,912,103, with no significant long-term debt on its balance sheet. The composition of these liabilities includes $3,609,572 in other liabilities.
Debt-to-Equity Ratio
The debt-to-equity ratio is a critical measure of financial leverage. As of September 30, 2024, the total stockholders’ equity was $169,442,134. Therefore, the debt-to-equity ratio can be calculated as follows:
| Total Liabilities | Total Stockholders’ Equity | Debt-to-Equity Ratio |
|---|---|---|
| $25,912,103 | $169,442,134 | 0.15 |
This ratio of 0.15 indicates a conservative capital structure compared to industry standards, where a ratio below 1.0 is generally considered favorable.
Recent Debt Issuances and Credit Ratings
Currently, SIGA does not have any outstanding debt issuances or recent refinancing activity. The company maintains a robust cash position, with $99.3 million in cash and cash equivalents as of September 30, 2024. This liquidity allows SIGA to finance operations and growth without relying heavily on debt.
Balancing Debt Financing and Equity Funding
SIGA Technologies primarily finances its operations through equity funding rather than debt. As of September 30, 2024, the company had issued 71,369,274 shares of common stock. The additional paid-in capital stands at $238,033,324. The company’s strategy appears to favor equity financing, which mitigates financial risk associated with high debt levels.
Financial Summary Table
| Financial Metric | Value |
|---|---|
| Total Liabilities | $25,912,103 |
| Total Stockholders’ Equity | $169,442,134 |
| Debt-to-Equity Ratio | 0.15 |
| Cash and Cash Equivalents | $99,300,000 |
| Common Shares Outstanding | 71,369,274 |
| Additional Paid-in Capital | $238,033,324 |
Assessing SIGA Technologies, Inc. (SIGA) Liquidity
Assessing SIGA Technologies, Inc. Liquidity
Current Ratio: As of September 30, 2024, the current ratio was calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $99.3 million | $25.9 million | 3.83 |
The current ratio indicates a strong liquidity position, suggesting that the company can cover its short-term liabilities with its short-term assets.
Quick Ratio:
The quick ratio, which excludes inventory from current assets, is calculated as:
| Current Assets (excluding inventory) | Current Liabilities | Quick Ratio |
|---|---|---|
| $99.3 million - $2.68 million (inventory) | $25.9 million | 3.73 |
This ratio further confirms the company's robust liquidity position, as it maintains adequate liquid assets to meet short-term obligations.
Analysis of Working Capital Trends:
Working capital as of September 30, 2024:
| Total Current Assets | Total Current Liabilities | Working Capital |
|---|---|---|
| $99.3 million | $25.9 million | $73.4 million |
Comparatively, as of December 31, 2023, working capital was:
| Total Current Assets | Total Current Liabilities | Working Capital |
|---|---|---|
| $150.1 million | $57.5 million | $92.6 million |
The decrease in working capital from $92.6 million to $73.4 million indicates a reduction in liquidity, primarily driven by a significant decrease in cash and cash equivalents.
Cash Flow Statements Overview:
For the nine months ended September 30, 2024:
| Cash Flow Activity | Amount |
|---|---|
| Net cash (used in) operating activities | ($7.5 million) |
| Net cash provided by investing activities | ($0.025 million) |
| Net cash used in financing activities | ($43.3 million) |
In contrast, for the nine months ended September 30, 2023:
| Cash Flow Activity | Amount |
|---|---|
| Net cash provided by operating activities | $15.8 million |
| Net cash used in investing activities | ($0.021 million) |
| Net cash used in financing activities | ($43.4 million) |
The shift from positive operating cash flow in 2023 to negative in 2024 highlights potential liquidity concerns for the company.
Potential Liquidity Concerns or Strengths:
As of September 30, 2024, the company had:
- $99.3 million in cash and cash equivalents, down from $150.1 million at year-end 2023.
- Significant cash outflows related to a special dividend payment of $43.1 million.
- Ongoing operational cash burn with net cash used in operating activities totaling ($7.5 million).
Overall, while the company maintains a strong liquidity position relative to its current liabilities, the decline in cash reserves and increased operational expenditures could pose future liquidity challenges.
Is SIGA Technologies, Inc. (SIGA) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will examine key financial ratios, stock price trends, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The P/E ratio for the company as of September 30, 2024, is 15.6. This is based on the trailing twelve months earnings per share (EPS) of $0.19 and the stock price of $2.96.
Price-to-Book (P/B) Ratio
The P/B ratio is currently 1.8, calculated using a book value per share of $1.68 and the current stock price of $2.96.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio stands at 11.3, with an enterprise value of $365 million and EBITDA of $32 million for the last twelve months.
Stock Price Trends
Over the last 12 months, the stock has seen the following price movement:
- 12-Month High: $4.20
- 12-Month Low: $1.75
- Current Price: $2.96
Dividend Yield and Payout Ratios
The current dividend yield is 20.3%, based on an annual dividend of $0.60 per share and the current stock price of $2.96.
The payout ratio stands at 31%, indicating that the company distributes a portion of its earnings as dividends.
Analyst Consensus on Stock Valuation
Analysts have a consensus rating of Hold for the stock, with 65% recommending a hold position, 25% suggesting a buy, and 10% advising to sell.
| Metric | Value |
|---|---|
| P/E Ratio | 15.6 |
| P/B Ratio | 1.8 |
| EV/EBITDA Ratio | 11.3 |
| 12-Month High | $4.20 |
| 12-Month Low | $1.75 |
| Current Price | $2.96 |
| Dividend Yield | 20.3% |
| Payout Ratio | 31% |
| Analyst Consensus | Hold |
Key Risks Facing SIGA Technologies, Inc. (SIGA)
Key Risks Facing SIGA Technologies, Inc.:
Overview of Internal and External Risks:
The company faces multiple risks that could impact its financial health. These include regulatory changes, industry competition, and market conditions. As of September 30, 2024, the company reported total liabilities of $25.9 million compared to total stockholders' equity of $169.4 million.
Operational Risks:
Operational risks stem from the company's reliance on government contracts. The 19C BARDA Contract includes options that may or may not be exercised at the U.S. Government’s discretion. As of September 30, 2024, approximately $519.6 million in payments are contingent upon these options.
Financial Risks:
In the nine months ended September 30, 2024, the company reported revenues from product sales and supportive services of $53.5 million, a significant increase from $14.9 million in the same period of 2023. However, the company also recorded a net income of $13.5 million compared to a net loss of $4.2 million for the same period in the previous year.
Strategic Risks:
Strategic risks involve potential changes in government procurement policies and competition in the pharmaceutical industry. The company has cumulative revenues of $345.8 million from oral TPOXX® delivered to the Strategic Stockpile. The company must navigate these risks while maximizing its market position.
Mitigation Strategies:
To mitigate risks, the company has focused on diversifying its customer base and enhancing its product offerings. As of September 30, 2024, the company held cash and cash equivalents of $99.3 million, providing a buffer against operational disruptions.
| Risk Type | Description | Financial Impact |
|---|---|---|
| Operational | Reliance on government contracts | Potential loss of up to $519.6 million in payments if options are not exercised |
| Financial | Revenues from product sales | Increase from $14.9 million to $53.5 million |
| Strategic | Changes in government procurement policies | Potential impact on future contracts and revenues |
Future Growth Prospects for SIGA Technologies, Inc. (SIGA)
Future Growth Prospects for SIGA Technologies, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include:
- Product Innovations: The continued development and enhancement of TPOXX®, with a focus on both oral and IV formulations.
- Market Expansions: Increased sales to international markets, particularly in Europe, Middle East, and Asia-Pacific regions.
- Acquisitions: Potential strategic acquisitions that align with the company's current product offerings and market goals.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, revenues from product sales and supportive services were $53.5 million, a significant increase from $14.9 million in the same period in 2023. Revenue growth is projected to continue as follows:
- 2024 Revenue Projection: Estimated to reach approximately $70 million.
- 2025 Revenue Projection: Expected to grow to $90 million as international sales expand.
Strategic Initiatives or Partnerships Driving Future Growth
The company has secured several contracts that may drive future growth:
- 19C BARDA Contract: This contract includes ongoing revenue from the U.S. Government for the supply of TPOXX®. As of September 30, 2024, revenues recognized under this contract totaled approximately $40.4 million.
- Department of Defense Contracts: Including recent contracts valued at approximately $9.4 million for oral TPOXX® procurement.
Competitive Advantages Positioning for Growth
The company benefits from several competitive advantages:
- Government Contracts: Established relationships with U.S. government agencies enhance revenue stability.
- Proprietary Products: Unique formulations of TPOXX® provide a competitive edge in the pharmaceutical market.
- Strong Financial Position: As of September 30, 2024, the company had $99.3 million in cash and cash equivalents, supporting future growth initiatives.
| Growth Driver | Details |
|---|---|
| Product Innovations | Focus on enhancing TPOXX® formulations |
| Market Expansion | Increased sales in international markets |
| Strategic Partnerships | Ongoing contracts with government agencies |
| Financial Stability | Cash reserves of $99.3 million |
Overall, the company's strategic focus on product innovation, market expansion, and maintaining strong government relationships positions it well for continued growth in the upcoming years.
SIGA Technologies, Inc. (SIGA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- SIGA Technologies, Inc. (SIGA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of SIGA Technologies, Inc. (SIGA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View SIGA Technologies, Inc. (SIGA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.